Intersect ENT (XENT) Tops Q1 EPS by 2c

Intersect ENT (NASDAQ: XENT) reported Q1 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $20.5 million versus the consensus estimate of $19.38 million.

GUIDANCE:

Intersect ENT sees Q2 2017 revenue of $22.5-22.7 million, versus the consensus of $21.73 million.

Intersect ENT sees FY2017 revenue of $89-91 million, versus the consensus of $88.04 million.

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c